VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.16 Million in AnaptysBio, Inc. $ANAB

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 17,250 shares of the biotechnology company’s stock, valued at approximately $1,164,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.06% of AnaptysBio as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd bought a new position in AnaptysBio in the 2nd quarter worth about $39,000. Smartleaf Asset Management LLC boosted its position in shares of AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 821 shares during the last quarter. Larson Financial Group LLC boosted its position in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the last quarter. Finally, Osaic Holdings Inc. raised its stake in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,326 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ANAB shares. Scotiabank cut shares of AnaptysBio to a “hold” rating and set a $70.00 price target for the company. in a research note on Tuesday, August 25th. HC Wainwright restated a “buy” rating and set a $95.00 price objective on shares of AnaptysBio in a research report on Monday, August 24th. Zacks Research downgraded shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. TD Cowen cut their target price on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Finally, Wolfe Research reissued an “outperform” rating and issued a $78.00 target price on shares of AnaptysBio in a research note on Monday, August 31st. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $79.85.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $53.87 on Friday. AnaptysBio, Inc. has a one year low of $11.40 and a one year high of $72.36. The firm’s 50 day simple moving average is $57.23 and its two-hundred day simple moving average is $59.24. The stock has a market capitalization of $1.60 billion, a P/E ratio of -49.88 and a beta of 0.71.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.